Endo receives subpoena on Lidoderm promotion

Share this article:
The US Department of Health and Human Services (HHS) has issued Endo Pharmaceuticals a subpoena regarding the promotion of its post-shingles pain patch Lidoderm. The subpoena requests documents from 1999 to the present related to the company’s knowledge of the use of Lidoderm for off-label uses for the treatment. Although physicians are allowed to prescribe drugs for off-label uses, pharmaceutical companies are not permitted to market drugs for non-approved uses. Endo said it would cooperate with the HHS’ request to provide the materials. “Endo has been and will continue to be firmly committed to promoting Lidoderm and all of Endo’s marketed products responsibly and appropriately within their currently approved indications,” said CEO Peter Lankau. “We have a strong ethics and compliance program. To that end, we routinely conduct extensive training for our employees to reinforce the importance of promotional practices that are within the FDA-approved indication.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...